MyOme's Innovative Research Enhances Coronary Artery Disease Prediction with Genetic Insights MyOme reveals groundbreaking research integrating genetic and clinical data for improved coronary artery disease risk prediction. Discover the implications today.

MyOme's Innovative Research Enhances Coronary Artery Disease Prediction with Genetic Insights #USA #Menlo_Park #MyOme #coronary_artery_disease #Polygenic_Risk

MyOme Unveils Zenith™ Diagnostics at ACMG 2026 with Natera's Partnership MyOme introduces its innovative Zenith™ portfolio in collaboration with Natera at ACMG 2026, enhancing rare disease diagnostics using cutting-edge methylation analysis.

MyOme Unveils Zenith™ Diagnostics at ACMG 2026 with Natera's Partnership #United_States #Menlo_Park #Natera #MyOme #Zenith

Thatch Partners with MyOme to Revolutionize Personalized Health Benefits with Genomics Thatch has unveiled its first genomics solution in partnership with MyOme, enhancing personalized health benefits for employees through genomic insights.

Thatch Partners with MyOme to Revolutionize Personalized Health Benefits with Genomics #USA #Genomics #San_Francisco #MyOme #Thatch

Illumina and MyOme Collaborate on Advances in Precision Medicine for Potential Healthcare Savings Illumina and MyOme have initiated a strategic partnership focused on improving precision medicine and risk assessment, potentially saving U.S. healthcare $200 billion annually.

Illumina and MyOme Collaborate on Advances in Precision Medicine for Potential Healthcare Savings #United_States #San_Diego #Precision_Medicine #Illumina #MyOme

MyOme and Ms.Medicine Unite to Transform Personalized Primary Care with Genomics MyOme and Ms.Medicine are collaborating to integrate comprehensive genomic testing into women's primary care, enhancing preventive healthcare.

MyOme and Ms.Medicine Unite to Transform Personalized Primary Care with Genomics #USA #Genomics #MyOme #MsMedicine #Menlo_Park,_Cincinnati

MyOme Introduces Groundbreaking Test for Prostate Cancer Risk Assessment MyOme has launched an integrated polygenic risk score test, enhancing the early detection of prostate cancer through genomic modeling and individualized risk assessments.

MyOme Introduces Groundbreaking Test for Prostate Cancer Risk Assessment #USA #Menlo_Park #Prostate_Cancer #MyOme #genomic_risk

MyOme Introduces the First National Proactive Health Network for Executive Clinics MyOme has unveiled a groundbreaking Proactive Health Network for concierge and executive health clinics, revolutionizing personalized medicine across the nation.

MyOme Introduces the First National Proactive Health Network for Executive Clinics #USA #Menlo_Park,_California #MyOme #Proactive_Health #Concierge_Clinics

MyOme Enhances Rare Disease Diagnostics with Cutting-Edge Genome Technologies MyOme has expanded its rare disease test to include groundbreaking tandem repeat expansions and mitochondrial genome analyses, enhancing diagnostic accuracy.

MyOme Enhances Rare Disease Diagnostics with Cutting-Edge Genome Technologies #United_States #Menlo_Park #Rare_Disease #MyOme #genome_analysis

MyOme Introduces Revolutionary Type 2 Diabetes Risk Assessment Technology to Enhance Proactive Health Solutions MyOme has launched its Type 2 Diabetes Integrated Polygenic Risk Score, enhancing proactive health assessments. This innovative tool utilizes genetic data to provide personalized diabetes risk evaluations.

MyOme Introduces Revolutionary Type 2 Diabetes Risk Assessment Technology to Enhance Proactive Health Solutions #United_States #Menlo_Park #Health #diabetes #MyOme

Neues zu Erkrankungen der Gebärmutter - Gute Pillen - Schlechte Pillen Starke Menstruationen können auf eine Krankheit hindeuten. Doch nicht immer stecken Myome, Endometriose oder sogar Krebs dahinter.

Deuten starke Menstruationen immer auf eine behandlungsbedürftige Krankheit hin? Werft einen Blick in den letzten Newsletter, es geht um #Frauengesundheit, #Endometriose, #Myome und #Gebärmutterhalskrebs.

MyOme Collaborates with Mayo Clinic to Transform Preventative Healthcare with AI MyOme, a leading genome analysis company, joins Mayo Clinic's Platform_Accelerate to enhance preventive care using AI and clinical data.

MyOme Collaborates with Mayo Clinic to Transform Preventative Healthcare with AI #United_States #Menlo_Park #Mayo_Clinic #MyOme #Preventative_Care

MyOme and Collective Health Partner to Enhance Employee Wellness Through Genomic Insights MyOme and Collective Health have partnered to provide employers with access to whole-genome analysis tools, promoting preventative care and personal health management.

MyOme and Collective Health Partner to Enhance Employee Wellness Through Genomic Insights #United_States #Menlo_Park #MyOme #Whole-Genome #Collective_Health

Revolutionizing Employee Health: MyOme and Novi Health's Genome Testing Partnership MyOme and Novi Health join forces to integrate whole genome sequencing into workplace health programs, empowering employees with critical health insights.

Revolutionizing Employee Health: MyOme and Novi Health's Genome Testing Partnership #United_States #Genomics #Menlo_Park #MyOme #Novi_Health